Federal Circuit Reverses $41.8M Verdict in Seagen Cancer Drug IP Case

By Editorial Team

The Federal Circuit issued a precedential opinion on Tuesday, overturning a $41.8 million verdict against Daiichi Sankyo for infringing a patent related to a Seagen breast cancer treatment. The court ruled that the lower court erred in finding that the patent did not adequately describe the claimed invention or enable a skilled person to use it.

The case involved a patent covering monomethylvaline compounds capable of conjugation to ligands. The Federal Circuit's decision to reverse the verdict has significant implications for the parties involved, including Daiichi Sankyo, Seagen Inc., and AstraZeneca PLC.

Law firms representing the parties in this case included Covington & Burling, Morrison & Foerster, Paul Hastings, and Willkie Farr. The legal battle also involved government agencies such as the Patent Trial and Appeal Board, the U.S. Court of Appeals for the Federal Circuit, the U.S. District Court for the Eastern District of Texas, and the U.S. Patent and Trademark Office.

This development underscores the importance of thorough patent descriptions and enablement in intellectual property cases. The decision by the Federal Circuit serves as a reminder of the high standards required for patent protection and enforcement in the pharmaceutical and life sciences industries.